German next-gen checkpoint inhibitor startup reels in €40M

Bundles of Euro currency notes

iOmx Therapeutics has raised €40 million ($44.6 million) in a Series A round to get to proof-of-concept data for “several” of its first-in-class therapeutics to address novel immune checkpoint targets. The startup, formed earlier this year, aims to improve upon the efficacy of approved checkpoint inhibitors.

Heavyweights MPM Capital and Sofinnova Partners co-led the oversubscribed round, which also included Wellington Partners and Merck Ventures.

"The company combines all the key features we are looking for when investing: an exceptional management team, world class science, and a market breaking technology platform that has the potential to build a strong pipeline of proprietary and more efficacious cancer therapeutics," said Henrijette Richter, a partner at Sofinnova, in a statement.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

The German startup is based on systematic screening of human tumor cells to find new targets and then analyze their mechanism of action. It is basing its research efforts on 6 immune-oncology targets. The idea is to create "organ-specific tumor evasion strategies" as the basis of next-gen cancer immunotherapy.

It’s based on the work of co-founder Philipp Beckhove, who was with the German Cancer Research Center. iOmx was founded in March by Beckhove alongside Nisit Khandelwal, Patrick Baeuerle, Sebastian Meier-Ewert and Elmar Maier.

"The development of checkpoint inhibitors represents a major advance in the treatment of certain cancers. However, despite some truly transformative successes, to date only a minority of patients benefit from existing treatment options. We aim to bring the advances in immuno-oncology to a greater proportion of cancer patients," said Meier-Ewert, who is the company’s CEO.

He founded German oncology company GPC Biotech in 1997 and helped build that company as its CSO. He then went on to become a managing director for MPM Capital. As for GPC, it merged with Agennix in 2009, although the resulting company fizzled out in 2013.

Suggested Articles

By employing heart rate signals, physical activity and sleep quality, common Fitbit trackers may be able to predict the spread of the flu.

Nanox has raised $26 million to help fuel the development and commercialization of its Star Trek-inspired digital X-ray bed.

Oncology is clearly a major medical and societal issue, but one that sees too much focus from biopharmas at the expense of other killers.